Bioconjugates (ADCs, AOCs, RDCs) & Chemistry

We are moving bioconjugates forward.

14+ conjugates in clinic including radiolabeled, oncology, and oligonucleotides.

2000+ conjugates developed for critical assays, and lead candidate selections with over 400 ADCs produced.

50+ bioconjugation programs scaled up to produce multi gram batches.

Bioconjugates are sophisticated, powerful, and versatile. They have started to fulfill their therapeutic potential most prominently in oncology, with cytotoxic antibody-drug conjugates (ADCs) providing new, improved treatment options for cancer patients. We are a leading, fully integrated bioconjugate CDMO + CRO that offers forward-thinking, integrated bioconjugate development and manufacturing services, with streamlined end-to-end solutions like our advanced ThioBridge™ ADC design and development platform.

Bioconjugates such as Antibody-Drug Conjugates (ADCs), including Bispecific ADCs, Dual Payload ADCs, Antibody-Oligo Conjugates (AOCs) and Radioconjugates (RDCs) offer complex design and development challenges. A recent area of focus for Abzena to further improve the efficacy of ADCs, and address drug resistance issues, has been the development of dual-payload ADCs. Our streamlined solutions simplify the development process. Interconnected teams collaborate, offering full end-to-end support – all under one organization, accelerating your timelines to clinic and commercial manufacturing, specializing in:

Early de-risking & optimization
Linker payload design & synthesis
Process development & optimization
Formulation development
Analytical method development
Clinical to commercial manufacturing

Bioconjugation Capabilities

We ensure a robust and consistent bioconjugate manufacturing process from clinical to commercial scale. Our capabilities include:

Sartorius Sartoflow^® Smart and Advance TFF systems for scale-up development and production in process development at volumes from 100mL – 50L and 0.1 – 2.1 m² membrane surface area allowing for straightforward transfer to cGMP manufacturing
Sartorius Sartoflow^® Alpha Plus SU and FlexAct^® SU TFF systems for GMP manufacturing with volume ranges from 1 – 200L and up to 3.5 m² membrane surface area

Full complement of AKTA FPLC™ systems in process development including an AKTA Pilot FPLC skid in process development capable of batch purification of more than 250g of bioconjugates in a day
AKTA Ready Gradient chromatography skid in GMP manufacturing suite capable of batch purification of greater than 1kg bioconjugate in a day
Conjugation reaction stirring capabilities include rocking motion mixers of volumes up to 50L and Sartorius LevMixer® pallet tanks from 50 – 1000L volume capacity

ThioBridge™ Info Sheet

ThioBridge™: Improved ADC Design & Delivery - Abzena

Linker technologies are critical when developing of Antibody-Drug Conjugates (ADCs). Most linkers, particularly those used in first-generation ADC bioconjugation have limitations. The impact, safety and efficacy of the ADC can be compromised. ThioBridge™ was developed by Abzena to overcome those limitations and improve the design and delivery of ADCs.

Download Info Sheet Discover ThioBridge™

What sets our bioconjugation services and solutions apart?

Leading end-to-end bioconjugation services across multiple modalities including ADCs, AOCs, Radioconjugates (RDCs) and more.
We are integrated in our approach to bioconjugate development combining design and production with functional assessment and biophysical characterization.
Through a comprehensive technology transfer process, we deliver a successful scale-up model to ensure a consistent bioconjugate manufacturing process from clinical to commercial.
We proactively collaborate with your team to de-risk the pathway of your bioconjugate to commercialization, ensuring manufacturability, moving quality medicine forward to patients.
We continue to pursue advances in technology, leverage our experience in a diverse range of bioconjugation platforms extending beyond ThioBridge™.
We expertly design and deliver solutions for small molecule intermediates including high potency chemistry, linker payload, payload-linker chemical intermediates.
Bioconjugation processes are developed and transferred to our cGMP manufacturing team minimizing process transfer challenges – here we can develop new innovative processes, when needed, to meet your program needs.
We develop the most effective processes for manufacturing at toxicology, clinical, and commercial scale using quality by design (QbD) principles.

Specialized Bioconjugation Services

Building on the unmatched expertise of our scientists, the IP we’ve generated, and our advanced facilities in the UK and US, we have everything you need to implement fully integrated commercial bioconjugation & ADC development and manufacturing programs.

We offer access to genuine scientific experts, streamlined development solutions, interconnected teams and full end-to-end support – all under one organization.

View ADC toolbox

Bioconjugates: Increasing Diversity & Applications

Bioconjugation has emerged as a cornerstone technology, enabling precise drug delivery, whilst enhancing therapeutic efficacy and reducing adverse effects. In our latest whitepaper our bioconjugation experts have explored the variety of conjugate types that are now accessible, each designed to enhance medical outcomes in various therapeutic areas.

Download Whitepaper

Bioconjugates & Chemistry Services

Moving medicines forward created with bioconjugates such as ADCs, AOCS and RDCs, and linker payloads is where we excel. Abzena is the leading, fully integrated, bioconjugate CDMO + CRO services provider through to commercialization.

Linker Payload

Supporting candidate ranking and lead selection, we determine the optimal design of linker payload architecture and profiling.

Why Abzena?

Leadership Team

Partners

Quality

Our History

Locations

Testimonials

Awards & Achievements

Ask Abzena

Antibody Discovery

Antibody Design

Antibody Development

Analytics & Bioassays

Immunogenicity Assays

Cell Line Development

Formulation Development

Process Development

cGMP Manufacturing

Linker Payload

Bioconjugate Design

Bioconjugate Development

Chemistry & Polymers

Analytics & Bioassays

Immunogenicity Assays

Formulation Development

Process Development

cGMP Manufacturing

Enhanced Cell Line Development

Smarter Immunogenicity Testing

De-Risked Drug Developability

Rapid Analytical Data

Advanced Antibody Humanization

What are your goals?

What development stage are you at?

Improved ADC Design & Delivery

Effective Deimmunized Proteins

Case Studies

Info Sheets

Posters & Publications

Whitepapers

Webinars & Videos

Articles

Bioconjugates (ADCs, AOCs, RDCs) & Chemistry

We are moving bioconjugates forward.

14+ conjugates in clinic including radiolabeled, oncology, and oligonucleotides.

2000+ conjugates developed for critical assays, and lead candidate selections with over 400 ADCs produced.

50+ bioconjugation programs scaled up to produce multi gram batches.

Bioconjugation Capabilities

ThioBridge™ Info Sheet

What sets our bioconjugation services and solutions apart?

Specialized Bioconjugation Services

Bioconjugates: Increasing Diversity & Applications

Bioconjugates & Chemistry Services

Linker Payload

Bioconjugate Design

Bioconjugate Development

Complex Chemistry & Polymers

Analytics & Bioassays

Immunogenicity Assays

Formulation Development

Process Development & Optimization

cGMP Bioconjugate Manufacturing

Discover ThioBridge™

About ThioBridge™

ThioBridge™ Info Sheet

ThioBridge™ Case Study

Bioconjugation Insights

Whitepaper: Increasing Diversity & Applications of Bioconjugates

Whitepaper: Designing, Selecting & Developing Bioconjugates

Info Sheet: Streamlining Bioconjugation for ADC Development

Info Sheet: Complex Chemistry for ADCs

Info Sheet: Advanced Linker Payload Solutions

Case Study: Fab-Oligo Conjugation Success